369 related articles for article (PubMed ID: 37334350)
1. The application and research progress of anti-angiogenesis therapy in tumor immunotherapy.
Tu J; Liang H; Li C; Huang Y; Wang Z; Chen X; Yuan X
Front Immunol; 2023; 14():1198972. PubMed ID: 37334350
[TBL] [Abstract][Full Text] [Related]
2. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Li S; Zhang Q; Hong Y
Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenesis: Opening a new window for immunotherapy.
Guo F; Cui J
Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor vascularization: promising strategies for vascular normalization.
Zheng R; Li F; Li F; Gong A
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
[TBL] [Abstract][Full Text] [Related]
6. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y; Jung K
Exp Mol Med; 2023 Nov; 55(11):2308-2319. PubMed ID: 37907742
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
Choi SH; Yoo SS; Lee SY; Park JY
Arch Pharm Res; 2022 Apr; 45(4):263-279. PubMed ID: 35449345
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy.
Xiao M; Shi Y; Jiang S; Cao M; Chen W; Xu Y; Xu Z; Wang K
Front Oncol; 2022; 12():1039378. PubMed ID: 36523993
[TBL] [Abstract][Full Text] [Related]
10. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
11. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.
Shafqat A; Omer MH; Ahmed EN; Mushtaq A; Ijaz E; Ahmed Z; Alkattan K; Yaqinuddin A
Front Immunol; 2023; 14():1200941. PubMed ID: 37520562
[TBL] [Abstract][Full Text] [Related]
13. The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment.
Hu H; Chen Y; Tan S; Wu S; Huang Y; Fu S; Luo F; He J
Front Immunol; 2022; 13():802846. PubMed ID: 35281003
[TBL] [Abstract][Full Text] [Related]
14. Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications.
Zhou S; Zhang H
Anticancer Agents Med Chem; 2020; 20(7):768-776. PubMed ID: 32031076
[TBL] [Abstract][Full Text] [Related]
15. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
Nikmaneshi MR; Jain RK; Munn LL
PLoS Comput Biol; 2023 Jun; 19(6):e1011131. PubMed ID: 37289729
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside.
Shamshiripour P; Hajiahmadi F; Lotfi S; Esmaeili NR; Zare A; Akbarpour M; Ahmadvand D
Front Immunol; 2022; 13():859633. PubMed ID: 35757736
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment.
Jasim SA; Farber IM; Noraldeen SAM; Bansal P; Alsaab HO; Abdullaev B; Alkhafaji AT; Alawadi AH; Hamzah HF; Mohammed BA
Microvasc Res; 2024 Jul; 154():104691. PubMed ID: 38703993
[TBL] [Abstract][Full Text] [Related]
18. [Vascular normalization and cancer immunotherapy].
Zeng J; Yuan D; Liu H; Song Y
Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):273-6. PubMed ID: 24667268
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor.
Shen R; Peng L; Zhou W; Wang D; Jiang Q; Ji J; Hu F; Yuan H
J Control Release; 2022 Sep; 349():550-564. PubMed ID: 35841997
[TBL] [Abstract][Full Text] [Related]
20. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.
Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y
Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
